INTRODUCTION
============

Sarcomas are a rare form of cancer that account for less than 1% of new adult malignancies \[[@b1-aps-2019-00780]\]. Historically, the treatment of extremity sarcomas was amputation of the affected limb \[[@b2-aps-2019-00780]\]. However, in order to improve quality of life and functional outcomes, more recent management emphasizes that adequate control of the disease can be achieved through limb-sparing surgery \[[@b3-aps-2019-00780]\]. For appropriately selected patients, chemotherapy and radiation have also demonstrated an overall survival advantage \[[@b4-aps-2019-00780]\].

The NCCN (National Comprehensive Cancer Network) guidelines state that definitive surgical resection with negative margins is the mainstay for curative treatment \[[@b5-aps-2019-00780]\]. In cases of extensive resection, primary closure is seldom possible, and may require locoregional or free flap reconstruction \[[@b6-aps-2019-00780]\]. With limb-sparing surgical excision, the benefit of increased functionality comes at a cost of increased rates of wound complications \[[@b3-aps-2019-00780]\]. In order to limit the frequency of postoperative wound complications, it is imperative to identify high-risk patients who may require more aggressive monitoring and wound care.

Previously, a retrospective review examining the predictive factors of wound complications post-sarcoma reconstruction determined that the most predictive factor of complications was whether the procedure was delayed or immediate \[[@b2-aps-2019-00780]\]. Although the effect of timing of sarcoma reconstruction has been poorly investigated, several other retrospective studies correspondingly found higher rates of major wound complications when reconstruction was not done promptly after oncologic surgery \[[@b2-aps-2019-00780],[@b3-aps-2019-00780], [@b6-aps-2019-00780],[@b7-aps-2019-00780]\]. The purpose of this study was to compare outcomes of delayed and immediate reconstruction in the setting of sarcoma resection requiring flap reconstruction in the lower extremity.

METHODS
=======

After approval from the Institutional Research Ethics Board (approval number: 2017-3146), a retrospective review of all patients treated by the senior author for sarcoma reconstruction from January 2005 to July 2017 was performed. Two independent reviewers collected data from a combination of electronic and paper medical records. All patients who underwent vascularized tissue reconstruction using free flaps or pedicled flaps post-sarcoma resection were included. Patients who were lost to follow-up (\<3 months) or transferred to another institution were excluded from the study.

All lower extremity sarcomas requiring flap reconstructions were included, irrespective of tumor histopathology. Sarcoma resection was performed by the institution's orthopedic surgery team. Patients were classified as delayed or immediate depending on whether the reconstructive surgery occurred in the same procedure as the tumor resection. Demographic information, patient comorbidities and tumor characteristics were collected. Information on neoadjuvant and adjuvant chemotherapy and radiotherapy treatments were also recorded. The primary outcome of interest was early postoperative wound complications including: infection, dehiscence, hematoma, seroma, arterial thrombosis, venous thrombosis, and partial/total flap loss.

The outcomes between delayed and immediate reconstruction groups were compared using Fisher's exact test (categorical variables). For continuous variables (age, tumor size, and tumor depth), delayed and immediate reconstruction groups were compared using an unpaired t-test. Statistical significance was set at a P-value of 0.05. Means and frequencies were calculated for continuous variables and categorical data, respectively. All statistical analyses were carried out using GraphPad Prism 6 software (La Jolla, CA, USA).

RESULTS
=======

From January 2005 to July 2017, a total of 32 patients underwent flap (free or pedicled) reconstruction of the lower extremity at our sarcoma center. Seven patients were included in the delayed reconstruction group and 25 patients were included in the immediate reconstruction group. For patients who had a delay in reconstruction, the average delay between resection and reconstruction was 3.2 weeks, with a standard deviation of 1.6 weeks. Patients had a minimum follow-up time of 3 months.

Patient and tumor demographics
------------------------------

Patient demographics, pathological diagnosis, tumor size, and neo-/adjuvant therapy are described in [Table 1](#t1-aps-2019-00780){ref-type="table"}. There was an increased incidence of hypertension in the delayed reconstruction group (57.1% vs. 16.0%, P=0.047). In the immediate reconstruction group, there was an increased incidence of neoadjuvant radiotherapy (64.0% vs. 14.3%, P=0.033). There were no other significant differences between the two groups. A breakdown of the type of flap reconstructions is provided in [Table 2](#t2-aps-2019-00780){ref-type="table"}.

Complications
-------------

In order to assess the outcomes of reconstructive surgery, the wound and microvascular complications between delayed and immediate procedures are compared in [Table 3](#t3-aps-2019-00780){ref-type="table"}. Overall, all patients (7/7, 100%) who underwent delayed reconstruction procedures had at least one complication. The most common postoperative complication was infection (5/7, 71.4%). Other wound complications included hematoma (2/7, 28.6%), dehiscence (1/7, 14.3%), and seroma (1/7, 14.3%). Microvascular complications in the delayed reconstruction group included partial flap loss (2/7, 28.6%), total flap loss (1/7, 14.3%) and venous thrombosis (1/7, 14.3%).

In the immediate reconstruction group, seven patients had at least one complication (7/32, 28.0%). the most common complication was also infection (7/32, 28.0%). Other wound complications in the immediate reconstruction group included seroma (2/32, 8.0%) and dehiscence (1/32, 4.0%). Microvascular complications included total flap loss (1/32, 4.0%) and partial flap loss (1/32, 4.0%).

Overall, a significant increase in overall complication rate (100% vs. 28.0%, P=0.001) and hematoma (28.6% vs. 0.0%, P=0.042) was seen in the delayed reconstruction group.

DISCUSSION
==========

In order to improve functional outcomes, limb-salvage surgery has become the standard treatment for sarcomas of the extremity. The rate of complications in sarcoma procedures is between 30% and 40%, depending on supplemental neoadjuvant or adjuvant therapy \[[@b2-aps-2019-00780],[@b8-aps-2019-00780],[@b9-aps-2019-00780]\]. In particular, lower-extremity reconstruction has a tendency to have increased rates of complication and flap failure due to the scarcity of local soft tissue and blood supply \[[@b10-aps-2019-00780]-[@b12-aps-2019-00780]\]. Thus, identifying the procedural factors that contribute to high complication rates is important to help direct treatment guidelines. Our study aimed to investigate the effect of the timing of flap reconstruction, specifically in sarcomas of the lower extremity.

This study highlights that delayed flap reconstruction of the lower extremity is associated with an increased rate of wound complications compared to immediate reconstruction (100% vs. 28.0%, P=0.001). While our study focuses specifically on the lower extremity, the results remain consistent with the available literature, which comprised of small retrospective cohort studies \[[@b2-aps-2019-00780],[@b3-aps-2019-00780],[@b6-aps-2019-00780],[@b7-aps-2019-00780]\]. Sanniec et al. \[[@b7-aps-2019-00780]\] found that delaying reconstruction after sarcoma resection led to an increased number of infections requiring antibiotics (47.1% vs. 9.4%, P=0.0016). The authors postulate that immediate reconstruction of sarcoma defects have superior healing outcomes due to the introduction of healthy tissue to increase circulation and bacterial clearance \[[@b7-aps-2019-00780]\]. When delayed sarcoma reconstruction is necessary, they suggest that prophylactic antibiotics are to be considered as standard treatment. While we also report an increased rate of infection with delayed reconstruction (71.4% vs. 28.0%), the difference was not found to be significant (P=0.074).

In the current study, delayed reconstruction was associated with a significantly increased incidence of hematoma (28.6% vs. 0%, P=0.0423). Published studies have not previously observed this outcome. We hypothesize that delaying reconstruction may expose tissues and vessels that, even with careful dressing changes and wound care, may leave vessels susceptible to damage and/or desiccation. These open wounds might have also been infected, thus exposing the tissue to inflammation and altered hemostasis. Moreover, additional debridement due to the delayed nature of the reconstruction might have also increased the risk of hematoma in these cases. Another contributing factor may be the significantly increased rate of hypertension present in the delayed reconstruction group, as there is evidence of correlation between perioperative blood pressure and hematoma development \[[@b13-aps-2019-00780]\]. It is possible that this may have contributed to the observed increased rates of hematoma.

When comparing concurrent treatment, patients in the immediate reconstruction group had a significantly increased number of patients who underwent neoadjuvant radiotherapy. Although useful to diminish tumor sizes, it has been well-established that the cytotoxic effects of radiotherapy create an unfavorable environment for reconstructive surgery and wound healing \[[@b14-aps-2019-00780]\]. This is the second time that our group has not observed an increase in postoperative complications following neoadjuvant radiation therapy \[[@b15-aps-2019-00780]\].

Our sarcoma center incorporates treatment involving a multidisciplinary team of pathologists, radiologists, oncologists and surgeons. Outcomes of local control and survival are shown to be improved when treated at specialized sarcoma centers, which is defined as a hospital with a multidisciplinary team for managing sarcomas \[[@b16-aps-2019-00780]\]. Marre et al. \[[@b3-aps-2019-00780]\] found that late reconstructive management results in higher complication rates and can lead to subsequent worsening of functional outcomes and quality of life. They recommend that reconstructive surgeons are to be involved with the interdisciplinary team and decision-making process from day one of sarcoma management \[[@b3-aps-2019-00780]\].

The current study suggests a similar conclusion. In the delayed reconstruction group, plastic and reconstructive surgeons were only consulted following sarcoma resection. Patients are all seen by a surgical oncologist. If a large defect is anticipated, the patient is seen by a plastic and reconstructive surgeon pre-operatively for planning. However, if primary closure is anticipated, the patient is not seen by a reconstructive surgeon. All the patients in the delayed reconstruction group either had a larger than expected resection or a failed attempt at primary closure (dehiscence). Dehiscence was caused by infection (3 patients), seroma (1 patient), hematoma (1 patient) and unknown causes (2 patients). In contrast, plastic and reconstructive surgeons had already been involved in the patient care and management in the immediate reconstruction group. Early preoperative involvement of the plastic and reconstructive surgeon could potentially prevent delayed reconstruction by providing the most appropriate alternative to primary closure in these lower extremity resections that are at high risk of complications. Although primary closure is possible in certain cases, the reconstructive surgeon can provide a robust and reliable reconstructive option (e.g., vascularized tissue) that is more resistant to the inevitable complications in lower extremity sarcoma resections. Communication between the reconstructive surgeon and the remainder of the team is of utmost importance for the patient. Proper planning and clear communication can favor immediate reconstruction, obviating the potential risks with delayed procedures and the risks associated with general anesthesia.

The current study is not without limitations. As a single-center retrospective study with a relatively small number of patients, further studies are needed for proof of generalizability and causality. Moreover, delayed reconstructions may have been unavoidable due to longer and/or more complicated resections, predisposing these patients to higher complication rates. The patient population in the delayed reconstruction group may have also been at greater risk of complications after reconstruction, irrespective of the timing of the operation (plastic surgery was only consulted after a failed attempt at primary closure attempt). Given the retrospective nature of this study, we acknowledge that we were not able to collect an even sample size and that inevitably, selection bias may have occurred. Moreover, investigating the correlation between complication rate and days of delay would have been of interest, however, it was not possible with our data given that 100% of the patients in the delayed group had complications.

Future prospective and randomized controlled trials will hopefully evaluate the impact of delaying reconstruction, while controlling for the above confounding factors. While our results concur with previously published studies, it would be imperative to study the results of more centers with a prospective design and larger sample size.

In conclusion, this study suggests that delayed reconstruction following sarcoma resection of the lower extremity had a higher incidence of overall complications and hematoma formation. We emphasize the importance of early plastic and reconstructive surgeon referral and the necessity to closely monitor delayed reconstruction patients for complications.
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###### 

Patient and tumor demographics

  Variable                                                      Delayed (n = 7)                                              Immediate (n = 25)                                           Overall (n = 32)                                               P-value^[a)](#tfn1-aps-2019-00780){ref-type="table-fn"}^
  ------------------------------------------------------------- ------------------------------------------------------------ ------------------------------------------------------------ -------------------------------------------------------------- ----------------------------------------------------------
  Patient demographics                                                                                                                                                                                                                                   
   Age (yr)                                                     64.0 ± 19.5                                                  47.5 ± 19.9                                                  51.1 ± 20.7                                                    0.061
   Female sex                                                   4 (57.1)                                                     8 (40.0)                                                     14 (43.8)                                                      0.670
   Diabetes                                                     0 (0.0)                                                      3 (12.0)                                                     3 (9.4)                                                        ≥ 0.999
   Hypertension                                                 4 (57.1)                                                     4 (16.0)                                                     8 (25.0)                                                       0.047^[e)](#tfn5-aps-2019-00780){ref-type="table-fn"}^
   Dyslipidemia                                                 3 (42.9)                                                     4 (16.0)                                                     7 (21.9)                                                       0.157
   Smoking history                                              2 (28.6)                                                     4 (16.0)                                                     6 (18.8)                                                       0.590
   Peripheral vascular disease                                  1 (14.3)                                                     1 (4.0)                                                      2 (6.3)                                                        0.395
  Pathological diagnosis                                                                                                                                                                                                                                 
   Soft tissue sarcoma                                          3 (42.9)                                                     19 (76.0)                                                    22 (68.8)                                                      0.166
   Bony                                                         4 (57.1)                                                     6 (24.0)                                                     10 (31.3)                                                      
  Tumor characteristics                                                                                                                                                                                                                                  
   Size (cm)^[b)](#tfn2-aps-2019-00780){ref-type="table-fn"}^   15.7 ± 9.0                                                   9.0 ± 9.5^[c)](#tfn3-aps-2019-00780){ref-type="table-fn"}^   10.9 ± 10.1^[c)](#tfn3-aps-2019-00780){ref-type="table-fn"}^   0.059
   Depth (cm)                                                   8.1 ± 3.7^[d)](#tfn4-aps-2019-00780){ref-type="table-fn"}^   5.5 ± 4.5^[d)](#tfn4-aps-2019-00780){ref-type="table-fn"}^   6.0 ± 4.4^[d)](#tfn4-aps-2019-00780){ref-type="table-fn"}^     0.248
   Bone resection                                               4 (57.1)                                                     5 (20.0)                                                     9 (28.1)                                                       0.076
  Neo/adjuvant therapy                                                                                                                                                                                                                                   
   Neoadjuvant chemotherapy                                     2 (28.6)                                                     4 (16.0)                                                     6 (18.8)                                                       0.590
   Adjuvant chemotherapy                                        4 (57.1)                                                     5 (20.0)                                                     9 (28.1)                                                       0.076
   Neoadjuvant radiotherapy                                     1 (14.3)                                                     16 (64.0)                                                    17 (53.1)                                                      0.033^[e)](#tfn5-aps-2019-00780){ref-type="table-fn"}^
   Adjuvant radiotherapy                                        3 (42.9)                                                     9 (36.0)                                                     12 (37.5)                                                      ≥ 0.999

Values are presented as mean±SD or number (%).

Fisher exact test was used for discrete variables. Unpaired t-test was used for continuous variables;

Size refers to the length of the greatest dimension;

Includes 24 samples, 1 did not report size;

Only includes samples with a reported depth (bony sarcomas were not included);

Statistically significant, P\<0.05.

###### 

Flap selection

  Flap                                     Delayed (n = 7)   Immediate (n = 25)
  ---------------------------------------- ----------------- --------------------
  Free flaps                                                 
   ALT                                     0                 1
   Latissimus dorsi                        0                 1
   FRFF                                    0                 6
   VRAM                                    1                 0
  Pedicled flaps (myocutaneous)                              
   Gastrocnemius                           1                 9
   Rectus femoris                          1                 0
   Rectus abdominis                        2                 2
   Vastus lateralis                        1                 0
   Gracilis/Adductor longus                1                 1
  Pedicled flaps (axial fasciocutaneous)                     
   Reverse superficial sural artery        0                 2
   Internal pudendal artery                0                 1
  Other                                    0                 2

ALT, anterolateral thigh flap; FRFF, free radial forearm flap; VRAM, vertical rectus abdominis flap.

###### 

Complications

  Complication                                                          Delayed (n = 7)   Immediate (n = 25)   P-value
  --------------------------------------------------------------------- ----------------- -------------------- --------------------------------------------------------
  Wound complications                                                                                          
   Dehiscence                                                           1 (14.3)          1 (4.0)              0.395
   Hematoma                                                             2 (28.6)          0                    0.042^b)^
   Seroma                                                               1 (14.3)          2 (8.0)              0.536
   Infection                                                            5 (71.4)          7 (28.0)             0.074
  Microvascular complications                                                                                  
   Venous thrombosis                                                    1 (14.3)          0                    0.219
   Arterial thrombosis                                                  0                 0                    ≥ 0.999
   Total flap loss^[a)](#tfn6-aps-2019-00780){ref-type="table-fn"}^     1 (14.3)          1 (4.0)              0.395
   Partial flap loss^[a)](#tfn6-aps-2019-00780){ref-type="table-fn"}^   2 (28.6)          1 (4.0)              0.113
  Overall complications                                                 7 (100)           7 (28.0)             0.001^[b)](#tfn7-aps-2019-00780){ref-type="table-fn"}^

Values are presented as number (%).

Includes free and pedicled flaps;

Statistically significant, P\<0.05.

[^1]: This article was presented as a free paper at the 36th International Meeting of the Korean Society for Aesthetic Plastic Surgery on April 8, 2018, in Seoul, Korea.
